LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

22.8 -1.21

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.69

Máximo

23.13

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.597 51.415
BPA	0.468
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+49.52% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-40M 1.7B
Apertura anterior	24.01
Cierre anterior	22.8

Noticias sobre sentimiento de mercado

By Acuity

50%

171 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

18.57 / 18.75 Soporte y Resistencia

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 may 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 may 2026, 22:12 UTC

Ganancias

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 may 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs

15 may 2026, 00:00 UTC

Ganancias

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 may 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 may 2026, 23:56 UTC

Charlas de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 may 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 may 2026, 23:47 UTC

Ganancias

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 may 2026, 23:47 UTC

Ganancias

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 may 2026, 23:28 UTC

Charlas de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 may 2026, 23:00 UTC

Charlas de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 may 2026, 22:35 UTC

Charlas de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 may 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 may 2026, 22:06 UTC

Charlas de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 may 2026, 22:00 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q EPS 18c >NU

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q Rev $4.97B >NU

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

49.52% repunte

Estimación a 12 Meses

Media 34.6 USD 49.52%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

171 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.